Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 16/20 | 0.70 |
| ▸ | PGR | P06401 | 5/20 | 0.58 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.53 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.53 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6282015 | 0.87 | CYP11B1 (0.61) | NR3C1PGRNPBWR1CYP11B1CYP11B2 | |
| SCHEMBL4784971 | 0.85 | NR3C1 (0.63) | NR3C1PGRCYP11B1CYP11B2 | |
| SCHEMBL836018 | 0.84 | NR3C1 (0.78) | NR3C1PGRCYP11B2 | |
| SCHEMBL27765743 | 0.84 | NR3C1 (0.58) | NR3C1PGRCYP11B1CYP11B2 | |
| SCHEMBL27787547 | 0.82 | NR3C1 (0.55) | NR3C1PGRCYP11B1CYP11B2 | |
| SCHEMBL836751 | 0.81 | CYP11B2 (0.67) | NR3C1PGRCYP11B1CYP11B2 | |
| SCHEMBL6185201 | 0.80 | CYP11B2 (0.59) | NR3C1PGRNPBWR1MCHR1CYP11B1 | |
| SCHEMBL27787555 | 0.80 | NR3C1 (0.55) | NR3C1PGRCYP11B1CYP11B2 | |
| SCHEMBL27787554 | 0.79 | NR3C1 (0.54) | NR3C1PGRNPBWR1MCHR1CYP11B1 | |
| SCHEMBL5135413 | 0.78 | CYP11B2 (0.71) | NR3C1PGRCYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919332-B2 | N-substituted-heteroaryloxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors | PFIZER INC. (US) | 2005-07-19 | — | — | US | disclosed |
| EP-1507535-A1 | PYRIMIDINE-2,4,6-TRIONE METALLO-PROTEINASE INHIBITORS | Pfizer Products Inc. (US) | 2005-02-23 | — | — | EP | disclosed |
| US-20030232849-A1 | N-substituted-heteroaryloxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors | PFIZER INC. | 2003-12-18 | — | — | US | disclosed |
| WO-2003090751-A1 | PYRIMIDINE-2, 4, 6-TRIONE METALLO-PROTEINASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232849-A1 | N-substituted-heteroaryloxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors | MMP8, MMP9, MMP1 | NR3C1 358/4885PGR 610/4885NPBWR1 2009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.